https://pkcreceptor.com/index.....php/double-blind-ran
Information were gotten from PROCLAIM, a randomized period III trial comparing two different chemotherapy regimens pemetrexed + cisplatin (PEM) vs. etoposide + cisplatin (ETO), in conjunction with radiotherapy (RT) to treat stage III non-squamous non-small mobile lung cancer tumors (NSCLC). We aimed to find out if SII measured in the mid-treatment screen for RT (days 3-4) is an important predictor of success, if the end result of PEM vs. ETO differs by quartile (Q
Like
Comment
Share
